Trial Profile
A Multi-center, Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of CSJ148 Compared to Placebo to Prevent Human Cytomegalovirus (HCMV) Replication in Stem Cell Transplant Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Feb 2020
Price :
$35
*
At a glance
- Drugs CSJ 148 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 03 Feb 2020 Primary endpoint (Number of participants who require preemptive HCMV therapy) has not been met published in the Antimicrobial Agents and Chemotherapy
- 03 Feb 2020 Results published in the Antimicrobial Agents and Chemotherapy
- 17 Jan 2017 Status changed from recruiting to completed.